Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ProQR ( (PRQR) ) has shared an announcement.
On October 20, 2025, ProQR Therapeutics announced that it received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 study of its investigational RNA editing oligonucleotide, AX-0810. This study, to be conducted in the Netherlands, will evaluate the safety, tolerability, and pharmacokinetics of AX-0810, which targets NTCP for the treatment of cholestatic diseases. The company also announced a virtual Investor and Analyst Event scheduled for November 3, 2025, to discuss the clinical development of AX-0810 and its potential impact on treating liver diseases.
The most recent analyst rating on (PRQR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenue and persistent losses. Technical analysis provides mixed signals, with some short-term bullish momentum but potential bearish pressure. Valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform. The company aims to create a new class of medicines for both rare and prevalent diseases by leveraging the body’s own RNA editing mechanisms to reverse mutations or modulate protein expression.
Average Trading Volume: 411,041
Technical Sentiment Signal: Buy
Current Market Cap: $292.5M
See more insights into PRQR stock on TipRanks’ Stock Analysis page.